Neutrophil‐Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis
Nataliia Pavliuchenko, Petr Daněk, Hana Malcová, Rudolf Horváth, Dita Cebecauerová, Tomáš BrdičkaObjective
Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil‐derived IL‐1β, and the adaptor protein PSTPIP2, but direct evidence in human CRMO is lacking. This study aims to translate findings from mouse models to human disease by investigating the role of neutrophils and PSTPIP2 in CRMO.
Methods
Blood samples from 34 patients with CRMO and 20 controls were analyzed by flow cytometry, biochemical assays, and transcriptomic profiling of purified neutrophils. Patients were evaluated across treatment groups (untreated, NSAIDs, zoledronate, or anti‐TNF therapy). Neutrophil activation, PSTPIP2 expression, inflammatory gene responses, and correlations with clinical parameters were assessed.
Results
CRMO neutrophils displayed chronic activation marked by reduced CD62L expression (p‐value p=0.0016; Mann Whitney test), which correlated with MRI lesion burden. PSTPIP2 protein levels were consistently decreased (p=0.0006) despite elevated mRNA expression (p=0.0005) and absence of coding mutations, suggesting inflammation‐associated post‐transcriptional regulation. Both neutrophil activation and PSTPIP2 downregulation normalized in patients receiving anti‐TNF therapy. Unlike murine models, IL1B and CXCL8 expression were not increased. Transcriptomic profiling (4 patients and 3 controls) identified enrichment of NF‐κB signaling, inflammatory and chemotaxis pathways, with upregulation of CCL4 , CCL4L2 , ATL1 , VNN1 , H2BC7 , LINC02207 , and downregulation of ISL2 . Several transcripts correlated with clinical measures of disease burden.
Conclusion
These findings identify neutrophil activation and inflammation‐sensitive PSTPIP2 deficiency as central features of human CRMO, suggest chemokines as potential biomarkers, and mechanistically explain why TNF blockade provides clinical benefit.